Filing Details

Accession Number:
0001209191-23-004732
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-24 20:08:49
Reporting Period:
2023-01-20
Accepted Time:
2023-01-24 20:08:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649989 Outlook Therapeutics Inc. OTLK Biological Products, (No Disgnostic Substances) (2836) 383982704
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1760511 Jeff Evanson C/O Outlook Therapeutics, Inc.
485 Route 1 South, Bldg F, Suite 320
Iselin NJ 08830
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-20 267,000 $1.11 745,975 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.